NOP

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
水曜日, 4月 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

AGCO moves to suspend liquor licence of Kelsey's Restaurant in Huntsville for over-service of alcohol leading to fatal car accident

Retrieved on: 
水曜日, 2月 14, 2024
Liquor, Injury, Sale, Alcohol, NOP, LAT, AGCO

The AGCO Registrar has reason to believe that several violations of the Liquor Licence and Control Act, 2019 (LLCA) and its Regulations occurred at this establishment.

Key Points: 
  • The AGCO Registrar has reason to believe that several violations of the Liquor Licence and Control Act, 2019 (LLCA) and its Regulations occurred at this establishment.
  • The AGCO holds liquor licensees to high standards for the safe and responsible sale of alcohol.
  • Liquor licence holders must ensure their customers are not served to intoxication or permit intoxication on their premises.
  • “All liquor licence holders in Ontario are required to meet their obligations for the safe and responsible sale of alcohol.

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Retrieved on: 
火曜日, 9月 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ketan, Pharma, Naloxone, Oxycodone, Food and Drug Administration, Opioid use disorder, ADHD, DSM-IV codes, OUD, VAS, FQ, Physical dependence, II, Pain, Visual analogue scale, NOP, Patient, Risk, MOP, Neuropathic pain, Pain management, Addiction, Drug, HAP, FDA, Tramadol, Food, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
  • The findings will be shared on Thursday, September 7, in a poster presentation at the 2023 PAINWeek conference in Las Vegas.
  • Study participants randomly received a single dose of placebo, cebranopadol 600 μg, cebranopadol 1000 μg, tramadol IR 600 mg or oxycodone IR 40 mg.
  • The difference between the good effects and bad effects of drugs have been linked to their abuse potential.

Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder

Retrieved on: 
月曜日, 8月 28, 2023
Research, Mental Health, Neurology, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Ketan, Pharma, Wayne State University, Opioid, Public, Initiative, ADHD, DSM-IV codes, Opioid use disorder, OUD, FQ, Heroin, Bangladesh Technical Education Board, Pain, Cocaine, NOP, National Institute on Drug Abuse, MOP, NIDA, Pain management, Drug, Schedule 2, FDA, NIH, Disease, Pharmaceutical industry, Tris

Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).

Key Points: 
  • Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).
  • Cebranopadol is an investigational, dual nociception/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist.
  • Further, cebranopadol has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment for OUD.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

TransMedics Completes Acquisition of Summit Aviation

Retrieved on: 
水曜日, 8月 16, 2023
Heart, Transmedicalism, Aviation, Freedom Air, Summit Air, Oklahoma City Air Logistics Complex, Acquisition, NOP, MD, Patient, Organ transplantation, Liver failure, Summit, Medical imaging, Management, Airline

ANDOVER, Mass., Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the closing of its previously announced acquisition of Summit Aviation, a premier U.S. charter flight operator.

Key Points: 
  • ANDOVER, Mass., Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the closing of its previously announced acquisition of Summit Aviation, a premier U.S. charter flight operator.
  • The acquisition enables the establishment of TransMedics Aviation as the first integrated national provider of air logistics dedicated exclusively to organ transplantation in the U.S.
    "We are delighted to complete the acquisition of Summit Aviation, which represents a critical element of TransMedics' strategy to build and manage a national transplant logistics network designed to expand the reach and coverage of the National OCS Program (NOP)," said Waleed Hassanein, MD, President and Chief Executive Officer.
  • "I want to take this opportunity to welcome the Summit team to the TransMedics team.
  • I also want to welcome Ben Walton in his new role as our new VP of Aviation Services."

ADAS and Autonomous Driving Tier 1 Chinese Companies Research Report 2023: Featuring HiRain Technologies, Baidu Apollo, Huawei and Neusoft Reach Among Others

Retrieved on: 
火曜日, 7月 4, 2023
Aion, MCU, Drive, L1, HPP, Backbone, Research report, Original equipment manufacturer, Survival, Mobileye, Supply chain, Lead, Research, NIO, SDV, Lynk, SAIC, Hongqi (marque), Local, NOP, NOA, AVP, DNN, Socs, Algorithm, Supervision, Lite, Architecture, ADAS, Ecosystem, SenseTime, ODIN, IM Motors, Build automation, Li Auto, Software, Satellite navigation device, Video game, Instrumentation, Network equipment provider, Road, Fine chemical, Huawei, Infineon Technologies

DUBLIN, July 4, 2023 /PRNewswire/ -- The "ADAS and Autonomous Driving Tier 1 Suppliers Research Report, 2023 - Chinese Companies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 4, 2023 /PRNewswire/ -- The "ADAS and Autonomous Driving Tier 1 Suppliers Research Report, 2023 - Chinese Companies" report has been added to ResearchAndMarkets.com's offering.
  • This report contains research on China's local tier 1 suppliers: build up software and hardware strength, and "besiege" driving-parking integration by three routes.
  • According to the publisher, in 2023 Q1 Freetech joined the camp of the top five L2+ ADAS suppliers in China.
  • The ADC30 domain controller under development, with 448TOPS computing power and 3*J5+2*TDA4VH+2*TC397, supports 11V5R3L, and enables L3 autonomous driving.

China ADAS Redundant System Strategy Research Report 2023: The Last Line of Safety for Intelligent Vehicles - ResearchAndMarkets.com

Retrieved on: 
火曜日, 6月 6, 2023
Automotive Manufacturing, Manufacturing, Great Wall Motor, EEA, Communication, Probability, L3, NGP, Volvo, Central processing unit, Qualcomm, NIO, JET, SUV, Lidar, DUS, NOH, Wey Mocha, NOP, NVIDIA, Architecture, EPS, ADAS, AI, SOA, Safety, Maintenance (technical), Automotive industry, Instrumentation

The "China ADAS Redundant System Strategy Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China ADAS Redundant System Strategy Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • In the future, redundant systems will become standard configurations for L3 and higher-level driving assistance.
  • When the intelligent driving fails in extreme cases, the intelligent cockpit can take over the vehicle and let it stop safely.
  • Examples include Jingwei Hirain Technologies that developed R-EPS, a fully redundant EPS for L2-L4 autonomous driving, in August 2022.

NIO Emerging Carmaker Strategy Research Report 2023: ES6, ET7 and EC6 were the Top Three Models by Sales - ResearchAndMarkets.com

Retrieved on: 
木曜日, 6月 1, 2023
Automotive Manufacturing, Manufacturing, Atmos, EC6, HD, EEA, Habit, NT2, ADAM, Smartphone, Evocation, Anxiety, OTA, NOP, Perception, IVI, Firefly, NIO, HUD, Lidar, BEV, ALPS, USS, NT3, Radar, ES6, Algorithm, NP, NT1, Architecture, City, Ecosystem, XR, ES7, Dolby Atmos, Navigation, AR, Software, Retail, Satellite navigation device, Rail transport, Instrumentation

The "Emerging Carmaker Strategy Research Report, 2023 - NIO" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Emerging Carmaker Strategy Research Report, 2023 - NIO" report has been added to ResearchAndMarkets.com's offering.
  • As ES7, ET7 and ET5 ("775") were delivered, they saw a rising share of sales.
  • By province, Zhejiang (26,747 units), Jiangsu (18,105 units) and Guangdong (15,626 units) ranked top three by sales.
  • At present, all the cars delivered by NIO are positioned as high-end models priced at higher than RMB300,000.

Dulce Vida Tequila Introduces New Ready-To-Drink Cocktails in Tetra Pak® Cartons

Retrieved on: 
水曜日, 5月 17, 2023
Taste, Friends, Farmer, Portable, National Organic Program, ABV, Tetra Pak, Ice, NOP, USDA, Agave, Certification, Liquor, Tetra

AUSTIN, Texas, May 17, 2023 /PRNewswire/ -- Today, Dulce Vida Tequila announces the launch of three new ready-to-drink cocktails in Tetra Brik® Aseptic 1000 Square cartons. Available in Margarita, Watermelon Margarita and Paloma, each Dulce Vida cocktail is crafted using real fruit juice, all natural ingredients and Dulce Vida Blanco Tequila as a base for a premium, portable, cocktail experience with none of the hassle, but all of the taste.

Key Points: 
  • Summer-Ready Margarita, Watermelon Margarita and Paloma Cocktails Made With Real Fruit, Now in a Portable and Sustainable Carton
    AUSTIN, Texas, May 17, 2023 /PRNewswire/ -- Today, Dulce Vida Tequila announces the launch of three new ready-to-drink cocktails in Tetra Brik® Aseptic 1000 Square cartons.
  • Dulce Vida Tequila launches new ready-to-drink cocktails in portable and sustainable Tetra Pak® Cartons.
  • "Dulce Vida is produced intentionally as part of our dedication to crafting the highest-quality organic tequila with sustainable practices.
  • Dulce Vida RTD Cocktails in Tetra Pak® cartons are 15% ABV and ideal to grab on-the-go and share with friends - just add ice for a delicious Margarita, Watermelon Margarita or Paloma.

AGCO moves to revoke the liquor sales licence of Afro-East Restaurant in Kitchener

Retrieved on: 
金曜日, 5月 5, 2023
Social responsibility, Requirement, Fire protection, Person, Kitchener, Sale, Certification, Notice of proposed rulemaking, Liquor Licence Board of Ontario, Liquor, City, NOP, Alcohol, Kitchener Fire Department, Liquor Control Act 1988, AGCO, Administrative Monetary Penalty, Alcohol and Gaming Commission of Ontario, Safety, Property management, Restaurant, Tribunals Ontario

TORONTO, May 05, 2023 (GLOBE NEWSWIRE) -- The Deputy Registrar of the Alcohol and Gaming Commission of Ontario (AGCO) has issued a Notice of Proposal (NOP) to revoke the liquor sales licence of Afro-East Restaurant, located at 91 Queen St S, Kitchener, ON.

Key Points: 
  • TORONTO, May 05, 2023 (GLOBE NEWSWIRE) -- The Deputy Registrar of the Alcohol and Gaming Commission of Ontario (AGCO) has issued a Notice of Proposal (NOP) to revoke the liquor sales licence of Afro-East Restaurant, located at 91 Queen St S, Kitchener, ON.
  • During subsequent inspections conducted by the AGCO, the same back exterior gate was observed closed and chain locked once again.
  • Further, the licence holder failed to notify the AGCO of these charges as required by a condition on its liquor sales licence.
  • AGCO inspectors observed the licence holder permitting patrons to remove liquor from the licensed premises.